upcoming glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our Medicare GLP-1 Drug Coverage -
Description
The active ingredient in semaglutide GLP-1 injections is a type of GLP-1 receptor agonist

It may be reasonable to focus on whether the combination of GLP-1RAs and SGLT2is, which are expected to have complementary effects based on large-scale clinical trial results, can further reduce cardiovascular and renal events in patients with diabetes

Talk to your provider about how to transition off the medication safely if pregnancy is planned

Darwish L, Beroncal E, Sison MV, Swardfager W

Glycemic and cardiometabolic effects of rare sugars allulose and tagatose: a systematic review and meta-analysis of controlled human intervention trials

Do GLP-1 analogues have an impact on bone health